---
title: 'Special FDA designations for drug development: orphan, fast track, accelerated
  approval, priority review, and breakthrough therapy'
date: '2023-11-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37962724/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231114170859&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: Special FDA designations shorten clinical development and
  FDA approval times for new drugs treating rare and severe diseases with unmet medical
  needs. Special-designated drugs offer a greater clinical benefit to patients. However,
  physicians, patients, and insurers must be aware that special-designated drugs are
  often approved based on non-robust trials, associated with more unrecognized side
  effects, and sold for higher ...'
disable_comments: true
---
CONCLUSION: Special FDA designations shorten clinical development and FDA approval times for new drugs treating rare and severe diseases with unmet medical needs. Special-designated drugs offer a greater clinical benefit to patients. However, physicians, patients, and insurers must be aware that special-designated drugs are often approved based on non-robust trials, associated with more unrecognized side effects, and sold for higher ...